Travere Therapeutics, Inc. 8-K

What Happened
Travere Therapeutics, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2025 by filing a Form 8‑K on February 19, 2026. The company issued a press release reporting those results; the press release and accompanying information are attached to the 8‑K as Exhibit 99.1. The report was signed by CEO Eric Dube.

Key Details

• Filing date: February 19, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period covered: quarter and fiscal year ended December 31, 2025.
• Press release attached as Exhibit 99.1; interactive XBRL cover page included as Exhibit 104.
• Form 8‑K was executed by Eric Dube, Chief Executive Officer.

Why It Matters
Earnings releases provide updated information on revenue, profitability and business trends that can affect the stock price and investor decisions. This 8‑K notifies the market that Travere has released its Q4 and full‑year 2025 results; investors should read the attached press release (Exhibit 99.1) and any related filings (e.g., 10‑K or earnings presentation) for the actual financial figures and management commentary before making investment decisions.